Latest News and Press Releases

Second quarter revenue of $204 million, a year-over-year increase of 12% as reported and 13% organicGAAP operating income increased 1% year-over-year while adjusted operating income increased...

                  Fast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business ...

WALTHAM, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its second quarter 2026 financial results on Tuesday, July 28,...

WALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate...

WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication...

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate...

First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organicGAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-yearReiterating FY26...

WALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026....

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of...

WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...